WHO WE ARE
We specialize in the development of optimal personalized solutions for accelerating the drug development process.
We understand the arising needs of pharmaceutical manufacturers and thus strive to reduce their costs and time commitments, by providing them with the tools to guide the experimental process and avoid redundancy and investment into non-viable drug candidates.
In essence, “We Safeguard Success by Foreseeing the Pitfalls”. We accomplish this by implementing advanced concepts from medical science, biochemistry and mathematics into the design and construction of accurate predictive pharmacokinetics models, focusing primarily on living biological organisms.
The models we build are based on principles of optimality and self-organization; they are the culmination of decade-long researches and comparative analysis of experimental data. Most noteworthy is that we are able to simulate drug kinetics under a wide spectrum of extreme physiological conditions i.e. heavy physical load, hypoxia and hypoxemia, metabolic and respiratory pathologies. This helps determine the behavior of the drug candidate in at-risk patients.
DINmotion was founded in 2007 and is currently based in Montreal, Canada.
Here are a few publications from our team members:
-
Simulation of drug dynamic parameters and optimization models of the functional respiratory system in pharmacokinetic studies.
-
Integrated Approach to Systems Researches of Complex Problems of Medicine and Biology.
-
Mathematical Approach To Validation Of The Material Balance Type Simulation Models For Pharmacokinetics Studies.
Chief Scientific Officer BIO
STANISLAV POLINKEVYCH, MD, B.Sc
DINmotion President BIO
KONSTANTIN POLINKEVYCH, Ph.D. in Applied Mathematics and Computer Science
Dr. Polinkevych in his career has worked on numerous scientific and technical projects: the creation of algorithm generation systems for the control of moving objects; tools of mathematical modeling for systems of medical and biological nature; the creation of principles and the structure of functional systems in industry and warehousing. Based on the results of his research, he earned his Ph.D. in 1990.
Dr. Polinkevych is the author of many publications on design and development of complex computer systems and their implementations in commerce, biomedical, pharmaceutical, and aviation industries. Nevertheless, the primary focus of his researches was always placed on models of blood circulation system, building adequate simulation mechanisms on macro- and micro- levels. He actively participates in scientific conventions around the globe, keeps constant networking with experts in areas of medicine, physiology and new drug development.
Dr. Stanislav Polinkevych earned his B. Sc. in Biochemistry in 2012, and has since furthered his clinical interests with a Bachelor of Surgery Bachelor of Medicine degree in 2016. He gained first-hand experience in the early stages of drug development, starting with target identification and lead compound isolation in the context of novel therapy for diseases such as Cystic Fibrosis and Multiple Myeloma. Since then he has been an important contributor to the practical application of our PBPK models, and in furthering the clinical application of these models. He has been an active academic participant, engaging in several world congresses and conferences and furthering DINmotion’s academic presence.
He is greatly interested in the drug development optimization process, and reducing the cost burden and time delay for producing novel therapies.
OUR TEAM
Our researchers and consultants comprise an international network of experts with vast experience in the areas of human and animal physiology, biochemistry, medicine, pharmacology and mathematics. DINmotion President CONTACT US
AREAS OF IMPLEMENTATION
Our motivation is to help our clients transform a molecule into a medicine. Specifically, these are the areas and activities we target to reduce the cost and duration of drug development:
PREDICTION AND SIMULATION
-
Prediction and simulation of ADME parameters based on easily defined biological and physical properties of the chemical compound
-
Simulation of drug concentration profiles in specific organ systems and tissues, allowing to focus on specific systems pathologies
-
Prediction of compound accumulation and toxicity studies at capable extremes of bodily exertion
DOSAGE DETERMINATION & USER-FRIENDLY PRESENTATIONS
- Determination of dosage regimens for clinical trials
- User-friendly and comprehensive presentation of drug kinetic profiles
MODEL EXPANSION AND RE-MODELLING DURING OPTIMIZATION
- Re-modelling of pharmacokinetic profiles following alteration and optimization of the chemical structure under requirements for improved therapeutic action or needed compliance with specific ADME requirements.
- Expansion and design of models requiring additional methods of administration and metabolism to accommodate a new chemical structure.
VETERINARY PHARMACOLOGY
- We have expanded to include animal biological systems, and thus construct pharmacokinetic profiles for both companion animals and livestock
- Our models are applicable in a variety of dermatological preparations, dietary supplements and systemic medications for large livestock animals
FUTURE DEVELOPMENT
We pride ourselves on working in close collaboration with our clients to have a clear understanding of their vision and requirements. Consequently, the models we construct are tailored to specific features of the compound and its method of administration. Stemming from this, we are consistently involved in expansion into novel fields of pharmaceutical development. Particularly:
- Personalized medicine, ranging from creation of drug kinetics profiles in specific individuals as well as simulated population groups
Comments are closed.